Skye Bioscience, Inc. — Form 8-K/A
Filed August 19, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 28/100
What the filing says
Skye Bioscience filed an amended 8-K on August 20, 2026, reporting for the period of August 12, 2026. The filing discloses Item 3.03 (Material Modifications to Rights of Security Holders), but the specific details of what modifications were made, which security holders were affected, dollar amounts, share counts, or dates of effectiveness are not provided in the available filing header and metadata. The actual substance of the amendment cannot be determined from the excerpt supplied.
Why this rating
Item 3.03 flags potential security-holder rights changes, which could be material; however, no specifics provided. Without concrete details (terms, dilution %, dollar value), cannot assess true impact. Routine disclosure filing for a ~$130M company.
Extracted items
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.